Butenafine
Butenafine, Lotrimin Ultra (butenafine) is a small molecule pharmaceutical. Butenafine was first approved as Mentax on 1996-10-18. It is used to treat mycoses, tinea pedis, and tinea versicolor in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Butenafine, Lotrimin ultra (discontinued: Mentax, Mentax-tc)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| athletes foot | ANDA | 2024-07-03 |
| athletes foot ultra | ANDA | 2019-01-18 |
| butenafine hydrochloride | ANDA | 2023-12-07 |
| butenafine hydrochloride 1% | ANDA | 2023-04-12 |
| jock itch | ANDA | 2017-11-21 |
| lotrimin ultra | New Drug Application | 2024-07-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycoses | — | D009181 | B35-B49 |
| tinea pedis | EFO_0007512 | D014008 | B35.3 |
| tinea versicolor | EFO_0007439 | D014010 | B36.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | 2 | — | — | 2 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | 2 | — | — | 2 |
| Photoallergic dermatitis | D017454 | — | — | — | — | 1 | — | — | 1 |
| Phototoxic dermatitis | D017484 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tinea | D014005 | EFO_0007510 | B35.9 | 3 | 1 | — | — | — | 4 |
| Tinea pedis | D014008 | EFO_0007512 | B35.3 | 3 | 1 | — | — | — | 4 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Butenafine |
| INN | butenafine |
| Description | Butenafine is trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections. It has a role as an EC 1.14.13.132 (squalene monooxygenase) inhibitor and an antifungal drug. It is a tertiary amine and a member of naphthalenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 101828-21-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL990 |
| ChEBI ID | 3238 |
| PubChem CID | 2484 |
| DrugBank | DB01091 |
| UNII ID | 91Y494NL0X (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Butenafine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 338 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
732 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use